Clinical trial · Interventional
A Plant-Based Whole-Foods Meal Delivery Service for Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant
Implementing a Plant-Based Whole-Foods Meal Delivery Service for Patients Undergoing Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: A Pilot Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This clinical trial evaluates the impact of a plant-based whole-foods delivery service on the microbiome in patients with multiple myeloma undergoing an autologous hematopoietic cell transplant. An autologous hematopoietic cell transplant is a procedure in which blood-forming stem cells (cells from which all blood cells develop) are removed, stored, and later given back to the same person. Loss of microbial diversity within the intestinal tract has been associated with poor outcomes for patients receiving autologous stem cell transplantation. A plant-based whole meal delivery service may increase the intake of foods high in fiber and nutrients therefore improve microbial health during the peri-transplant period. In this pilot study, study investigators will explore the feasibility of this approach.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Biospecimen Collection | Procedure | — | UNRESOLVED |
| Dietary Intervention | Other | — | UNRESOLVED |
| Medical Chart Review | Other | — | UNRESOLVED |
| Questionnaire Administration | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Supportive care (meal delivery service)
- description
- Patients receive 3 meals per day and snacks delivered twice weekly and meet with dietitian once weekly on days -7 to 28. Patients undergo blood and stool sample collection on study.
- interventionNames
- Procedure: Biospecimen Collection
- Other: Dietary Intervention
- Other: Medical Chart Review
- Other: Questionnaire Administration
Primary outcomes (4)
- measure
- Enrollment rate
- timeFrame
- Up to 1 year
- description
- The proportion of eligible patients who consent to enroll in the study will be computed based on the number approached and estimated with 95% confidence intervals. Reasons for non-participation will be summarized.
- measure
- Collection rate
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Able to provide written informed consent prior to initiation of any study procedures * Planned first autologous stem cell transplantation for multiple myeloma * Planned outpatient treatment for the duration of transplantation (if admitted, the investigators will request that caregivers bring the meals/snacks to the hospital as they might with other food prepared at home) * Access to a refrigerator * Ability to reheat foods * Able to consume an oral diet at enrollment * Able to communicate clearly regarding aspects of the study: e.g. Give feedback on logistics and meals, in order to maximize the operational data the investigators can gather in this pilot study * At least 18 years of age Exclusion Criteria: * Major psychiatric diagnosis that impairs cognitive functioning or is not controlled at the time of the approach, as judged by the patient's medical team * Planned inpatient transplantation
References
Publications (2)
- DERIVEDUeland K, Elahi T, Rasmussen M, Wolfe AE, Purcell H, Chakka SR, Mirimo-Martinez M, Persinger H, Johnson K, Boynton AM, McMillen K, Byelykh M, Biernacki MA, Yeh AC, Ali N, Manjappa S, Wuliji N, Fredricks D, Bleakley M, Holmberg LA, Peled JU, Schenk J, Raftery D, Ma J, Hill GR, Neuhouser ML, Lee SJ, Markey KA. Plant-based whole-food diets are feasible during auto-HCT and are associated with dose-dependent microbiome modulation. Blood Adv. 2026 Jun 9:bloodadvances.2026020270. doi: 10.1182/bloodadvances.2026020270. Online ahead of print. PMID 42263665
- DERIVEDUeland K, Elahi T, Rasmussen M, Wolfe AE, Purcell H, Chakka SR, Mirimo-Martinez M, Persinger H, Johnson K, Boynton A, McMillen K, Byelykh M, Biernacki MA, Yeh AC, Ali N, Manjappa S, Wuliji N, Fredricks DN, Bleakley M, Holmberg LA, Schenk JM, Raftery D, Ma J, Hill GR, Neuhouser ML, Lee SJ, Markey KA. Plant-based whole-food diets are feasible during autologous stem cell transplantation and are associated with dose-dependent microbiome modulation: Results from a pilot clinical trial. medRxiv [Preprint]. 2026 Feb 4:2026.02.02.26345403. doi: 10.64898/2026.02.02.26345403. PMID 41674628